Announcement on Voluntary Disclosure of Receiving the Notice of Approval for Clinical Trials of HP560 Tablets for the Treatment of Myelofibrosis (Myeloproliferative Neoplasms)

About this update from Hinova Pharmaceuticals, Inc. Class A

Announcement on Voluntary Disclosure of Receiving the Notice of Approval for Clinical Trials of HP560 Tablets for the Treatment of Myelofibrosis (Myeloproliferative Neoplasms) The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Hinova Pharmaceuticals, Inc. Class A